Alberto López-Reyes

Prof. Alberto López-Reyes

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
GJGUADALUPE ELIZABETH JIMÉNEZ-GUTIÉRREZ
GUADALUPE ELIZABETH JIMÉNEZ-GUTIÉRREZ
LMLaura Edith Martínez-Gómez
Laura Edith Martínez-Gómez
CMCarlos Martinez-Armenta
Carlos Martinez-Armenta
CPCarlos Pineda
Carlos Pineda
GMGabriela Angelica Martínez-Nava
Gabriela Angelica Martínez-Nava
ALAlberto López-Reyes
Alberto López-Reyes
Sarcopenia is generally an age-related condition that directly impacts the quality of life. It is also related to chronic diseases such as metabolic dysfunction associated with diabetes and obesity. This means that everyone will be vulnerable to sarcopenia at some point in their life. Research to find the precise molecular mechanisms implicated in this condition can increase knowledge for the better prevention, diagnosis, and treatment of sarcopenia. Our work gathered the most recent research regarding inflammation in sarcopenia and new therapeutic agents proposed to target its consequences in pyroptosis and cellular senescence. Finally, we compared dual X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and ultrasound (US) as imaging techniques to diagnose and follow up on sarcopenia, indicating their respective advantages and disadvantages. Our goal is for the scientific evidence presented here to help guide future research to understand the molecular mechanisms involved in sarcopenia, new treatment strategies, and their translation into clinical practice.

1 October 2008 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ASAdriana Salazar-Montes
Adriana Salazar-Montes
LRLuis Ruiz-Corro
Luis Ruiz-Corro
ALAlberto López-Reyes
Alberto López-Reyes
ECEugenio Castrejón-Gómez
Eugenio Castrejón-Gómez
JAJuan Armendariz-Borunda
Juan Armendariz-Borunda

21 May 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
YCYessica Zamudio Cuevas
Yessica Zamudio Cuevas
KMKarina Martínez-Flores
Karina Martínez-Flores
JFJavier Fernández‐Torres
Javier Fernández‐Torres
YLYahir A. Loissell-Baltazar
Yahir A. Loissell-Baltazar
DMDaniel Medina-Luna
Daniel Medina-Luna
ALAlberto López-Reyes
Alberto López-Reyes
Gout is the most common inflammatory arthropathy of metabolic origin and it is characterized by intense inflammation, the underlying mechanisms of which are unknown. The aim of this study was to evaluate the oxidative stress in human fibroblast-like synoviocytes (FLS) exposed to monosodium urate (MSU) crystals, which trigger an inflammatory process. Human FLS isolated from synovial tissue explants were stimulated with MSU crystals (75 μg/mL) for 24 h. Cellular viability was evaluated by crystal violet staining, apoptosis was assessed using Annexin V, and the cellular content of reactive oxygen species (ROS) and nitrogen species (RNS) (O2 -, H2O2, NO) was assessed with image-based cytometry and fluorometric methods. In order to determine protein oxidation levels, protein carbonyls were detected through oxyblot analysis, and cell ultrastructural changes were assessed by transmission electron microscopy. The viability of FLS exposed to MSU crystals decreased by 30 % (P < 0.05), while apoptosis increased by 42 % (P = 0.01). FLS stimulated with MSU crystals exhibited a 2.1-fold increase in H2O2 content and a 1.5-fold increase in O2 - and NO levels. Oxyblots revealed that the spots obtained from FLS protein lysates exposed to MSU crystals exhibited protein carbonyl immunoreactivity, which reflects the presence of oxidatively modified proteins. Concomitantly, MSU crystals triggered the induction of changes in the morphostructure of FLS, such as the thickening and discontinuity of the endoplasmic reticulum, and the formation of vacuoles and misfolded glycoproteins. Our results prove that MSU crystals induce the release of ROS and RNS in FLS, subsequently oxidizing proteins and altering the cellular oxidative state of the endoplasmic reticulum, which results in FLS apoptosis.

30 October 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ALAlberto López-Reyes
Alberto López-Reyes
CMCarlos Martinez-Armenta
Carlos Martinez-Armenta
RERocio Espinosa-Velázquez
Rocio Espinosa-Velázquez
PVPaola Vázquez-Cárdenas
Paola Vázquez-Cárdenas
MCMarlid Cruz-Ramos
Marlid Cruz-Ramos
GMGabriela Angélica Martínez-Nava
Gabriela Angélica Martínez-Nava
Several countries around the world have faced an important obesity challenge for the past four decades as the result of an obesogenic environment. This disease has a multifactorial origin and it is associated with multiple comorbidities including type 2 diabetes, hypertension, osteoarthritis, metabolic syndrome, cancer, and dyslipidemia. With regard to dyslipidemia, hypertriglyceridemia is a well-known activator of the NLRP3 inflammasome, triggering adipokines and cytokines secretion which in addition induce a systemic inflammatory state that provides an adequate scenario for infections, particularly those mediated by viruses such as HIV, H1N1 influenza, and SARS-CoV-2. The SARS-CoV-2 infection causes the coronavirus disease 2019 (COVID-19) and it is responsible for the pandemic that we are currently living. COVID-19 causes an aggressive immune response known as cytokine release syndrome or cytokine storm that causes multiorgan failure and in most cases leads to death. In the present work, we aimed to review the molecular mechanisms by which obesity-associated systemic inflammation could cause a more severe clinical presentation of COVID-19. The SARS-CoV-2 infection could potentiate or accelerate the pre-existing systemic inflammatory state of individuals with obesity, via the NLRP3 inflammasome activation and the release of pro-inflammatory cytokines from cells trough Gasdermin-pores commonly found in cell death by pyroptosis.

9 April 2015 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
YCYessica Zamudio Cuevas
Yessica Zamudio Cuevas
CHCristina Hernández-Díaz
Cristina Hernández-Díaz
CPCarlos Pineda
Carlos Pineda
ARAnthony M. Reginato
Anthony M. Reginato
JCJorge Francisco Francisco Cerna Cortes
Jorge Francisco Francisco Cerna Cortes
ALAlberto López-Reyes
Alberto López-Reyes

17 February 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
LMLaura E. Martínez-Gómez
Laura E. Martínez-Gómez
BHBrígida Herrera-López
Brígida Herrera-López
CMCarlos Martinez-Armenta
Carlos Martinez-Armenta
SOSilvestre Ortega-Peña
Silvestre Ortega-Peña
MCMaría del Carmen Camacho-Rea
María del Carmen Camacho-Rea
ALAlberto López-Reyes
Alberto López-Reyes
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic, affecting more than 219 countries and causing the death of more than 5 million people worldwide. The genetic background represents a factor that predisposes the way the host responds to SARS-CoV-2 infection. In this sense, genetic variants of ACE and ACE2 could explain the observed interindividual variability to COVID-19 outcomes. In order to improve the understanding of how genetic variants of ACE and ACE2 are involved in the severity of COVID-19, we included a total of 481 individuals who showed clinical manifestations of COVID-19 and were diagnosed by reverse transcription PCR (RT-PCR). Genomic DNA was extracted from peripheral blood and saliva samples. ACE insertion/deletion polymorphism was evaluated by the high-resolution melting method; ACE single-nucleotide polymorphism (SNP) (rs4344) and ACE2 SNPs (rs2285666 and rs2074192) were genotyped using TaqMan probes. We assessed the association of ACE and ACE2 polymorphisms with disease severity using logistic regression analysis adjusted by age, sex, hypertension, type 2 diabetes, and obesity. The severity of the illness in our study population was divided as 31% mild, 26% severe, and 43% critical illness; additionally, 18% of individuals died, of whom 54% were male. Our results showed in the codominant model a contribution of ACE2 gene rs2285666 T/T genotype to critical outcome [odds ratio (OR) = 1.83; 95%CI = 1.01–3.29; p = 0.04] and to require oxygen supplementation (OR = 1.76; 95%CI = 1.01–3.04; p = 0.04), in addition to a strong association of the T allele of this variant to develop critical illness in male individuals (OR = 1.81; 95%CI = 1.10–2.98; p = 0.02). We suggest that the T allele of rs2285666 represents a risk factor for severe and critical outcomes of COVID-19, especially for men, regardless of age, hypertension, obesity, and type 2 diabetes.